- Home
- TDF vs IMMP Comparison
TDF vs IMMP Comparison
Compare TDF & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- IMMP
- Stock Information
- Founded
- TDF 1994
- IMMP 1987
- Country
- TDF Singapore
- IMMP Australia
- Employees
- TDF N/A
- IMMP N/A
- Industry
- TDF Finance/Investors Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- TDF Finance
- IMMP Health Care
- Exchange
- TDF Nasdaq
- IMMP Nasdaq
- Market Cap
- TDF 244.7M
- IMMP 251.8M
- IPO Year
- TDF N/A
- IMMP N/A
- Fundamental
- Price
- TDF $11.12
- IMMP $1.76
- Analyst Decision
- TDF
- IMMP Buy
- Analyst Count
- TDF 0
- IMMP 1
- Target Price
- TDF N/A
- IMMP $7.00
- AVG Volume (30 Days)
- TDF 79.2K
- IMMP 73.7K
- Earning Date
- TDF 01-01-0001
- IMMP 10-21-2025
- Dividend Yield
- TDF N/A
- IMMP N/A
- EPS Growth
- TDF N/A
- IMMP N/A
- EPS
- TDF N/A
- IMMP N/A
- Revenue
- TDF N/A
- IMMP $3,019,249.00
- Revenue This Year
- TDF N/A
- IMMP $50.37
- Revenue Next Year
- TDF N/A
- IMMP N/A
- P/E Ratio
- TDF N/A
- IMMP N/A
- Revenue Growth
- TDF N/A
- IMMP 24.11
- 52 Week Low
- TDF $7.15
- IMMP $1.32
- 52 Week High
- TDF $10.62
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- TDF 74.54
- IMMP 52.82
- Support Level
- TDF $10.55
- IMMP $1.63
- Resistance Level
- TDF $10.70
- IMMP $1.85
- Average True Range (ATR)
- TDF 0.16
- IMMP 0.07
- MACD
- TDF 0.05
- IMMP -0.01
- Stochastic Oscillator
- TDF 100.00
- IMMP 52.08
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.